Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years

Eitemau Tebyg

• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
  gan: Matanock, Almea, et al.
  Cyhoeddwyd: (2019)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  gan: Tomczyk, Sara, et al.
  Cyhoeddwyd: (2014)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  gan: Bennett, Nancy M., et al.
  Cyhoeddwyd: (2013)
• Summary of the National Advisory Committee on Immunization’s Statement on the re-immunization with polysaccharide 23-valent pneumococcal vaccine
  gan: Quach, C
  Cyhoeddwyd: (2015)
• 151. Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among US Medicare Beneficiaries ≥65 Years Old
  gan: Pilishvili, Tamara, et al.
  Cyhoeddwyd: (2018)